Elizabeth Olek

Liz serves as Kronos Bio’s senior vice president of Clinical Development, with responsibility for the planning, conduct and analysis of Kronos Bio’s clinical trials. She joined Kronos Bio in 2022 from Loxo Oncology at Lilly, where most recently she led the clinical development program for one of Loxo Oncology’s hematology drug candidates and was part of the team that was responsible for the development and approval of a thyroid and lung cancer medicine, selpercatinib. Prior to Loxo Oncology at Lilly, Liz worked at Puma Biotechnology, leading a clinical program in breast cancer. Before that, she consulted for several early-stage biotechnology companies, including Lumena Pharmaceuticals, aTyr Pharma and Receptos, advancing key clinical programs. Earlier in her career, Liz served as chief medical officer at Achillion Pharmaceuticals and in several leadership roles at Novartis. She started her pharmaceutical industry career at Genetics Institute and InterMune.

Liz received a Bachelor of Pharmacy degree from the University of the Sciences in Philadelphia, a medical degree from the Philadelphia College of Osteopathic Medicine and she received a Master of Public Health from the Boston University School of Public Health. She trained in Infectious Diseases at the Boston Medical Center and Finland Laboratory, spending several years in HIV/ID practice before joining the pharmaceutical industry.